Figure 1.

Melanoma metastases differentially express genes during therapy with sorafenib and/or dacarbazine. Exon array analysis on melanoma metastases specimens obtained from patients (n=9) before treatment (baseline), during treatment with sorafenib (day 10) and during treatment with sorafenib and dacarbazine (day 16). (A) Venn diagram of over/under differentially expressed genes in response to therapy and representing genes specific for or shared by different therapies. (B-C) Mining of functional gene associations was performed using Cytoscape, an open source application for visualization of gene interactions and pathway analysis (http://www.cytoscape.org). (B) Overview charts are specifying leading functional terms specific for or shared by sorafenib monotherapy or sorafenib plus dacarbazine. The size of the group indicates the number of the terms included in group. (C) Bar graphs representing gene ontology (GO) categories of genes specific for with sorafenib and/or dacarbazine combination, shared genes, their P-values and number of genes per GO category.